OverviewSuggest Edit

Natera (formerly known as Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory. The company offers a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; a single-gene mutation screening test to identify single-gene disorder; a carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier’s children.

TypePublic
Founded2004
HQSan Carlos, US
Websitenatera.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2018)975(+10%)
Job Openings103
Revenue (FY, 2018)$257.7 M(+23%)
Share Price (Nov 2019)$39.8 (+4%)

Key People/Management at Natera

Jonathan Sheena

Jonathan Sheena

Chief Technology Officer, Co-Founder
Mike Brophy

Mike Brophy

CFO
Steven Chapman

Steven Chapman

CEO
Robert Schueren

Robert Schueren

COO
Olesya Anisimova

Olesya Anisimova

VP of Finance, Corporate Controller
Debra Giorda

Debra Giorda

VP, Program Management
Show more

Natera Office Locations

Natera has an office in San Carlos
San Carlos, US (HQ)
201 Industrial Rd suite 410
Show all (1)

Natera Financials and Metrics

Natera Revenue

Embed Graph
View revenue for all periods
Natera's revenue was reported to be $257.65 m in FY, 2018 which is a 22.1% increase from the previous period.
USD

Revenue (Q3, 2019)

77.9m

Gross profit (Q3, 2019)

37.8m

Gross profit margin (Q3, 2019), %

48.5%

Net income (Q3, 2019)

(23.1m)

EBIT (Q3, 2019)

(21.1m)

Market capitalization (15-Nov-2019)

3.1b

Closing stock price (15-Nov-2019)

39.8

Cash (30-Sep-2019)

51.6m

EV

3.2b
Natera's current market capitalization is $3.1 b.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

217.1m210.9m257.7m

Revenue growth, %

14%(3%)22%

Cost of goods sold

135.6m139.6m166.1m

Gross profit

81.5m71.3m91.6m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

61.9m52.0m53.9m46.9m53.6m56.7m62.3m63.1m65.3m66.8m74.4m77.9m

Cost of goods sold

32.3m31.0m34.3m33.7m34.6m34.6m39.1m39.2m39.5m41.6m41.4m40.1m

Gross profit

29.6m21.0m19.6m13.2m19.1m22.0m23.3m23.9m25.8m25.2m33.0m37.8m

Gross profit Margin, %

48%40%36%28%36%39%37%38%40%38%44%48%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

15.3m12.6m46.4m

Accounts Receivable

13.4m8.3m62.2m

Prepaid Expenses

7.1m8.6m6.2m

Inventories

6.4m9.0m13.6m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

34.0m16.6m25.3m9.1m7.1m11.2m33.7m12.3m34.5m34.3m29.9m51.6m

Accounts Receivable

6.1m6.2m9.4m7.5m7.1m7.3m50.3m57.0m60.4m60.3m63.0m58.9m

Prepaid Expenses

3.9m5.6m9.4m7.9m5.7m6.4m5.9m7.2m6.4m5.6m5.7m14.0m

Inventories

6.7m8.9m9.2m8.2m7.4m9.2m11.9m12.3m12.2m13.7m15.2m12.5m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(95.8m)(136.3m)(128.2m)

Depreciation and Amortization

6.2m7.1m7.5m

Inventories

(2.1m)(3.1m)(4.9m)

Accounts Payable

1.3m217.0k3.8m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(8.7m)(31.8m)(57.9m)(36.0m)(63.7m)(90.8m)(32.9m)(66.7m)(96.3m)(34.1m)(66.5m)(89.6m)

Depreciation and Amortization

1.2m2.4m4.2m1.8m3.6m5.3m1.9m3.7m5.6m1.9m4.0m5.9m

Inventories

1.4m(800.0k)(1.2m)(2.0m)(1.1m)(3.2m)(3.0m)(3.5m)(3.5m)(216.0k)(1.8m)400.0k

Accounts Payable

1.8m2.2m1.7m(1.9m)2.0m(4.5m)51.0k(784.0k)967.0k(5.5m)(6.4m)(5.2m)
USDY, 2019

EV/EBIT

-151.1 x

EV/CFO

-65.9 x

Financial Leverage

4.5 x
Show all financial metrics

Natera Operating Metrics

Q1, 2016Q2, 2016Q3, 2016FY, 2016Q1, 2017Q2, 2017Q3, 2017FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019

Countries Covered

61 81 81

Covered Lives

200 m200 m200 m203 m195 m198 m198 m208 m200 m205 m205 m209 m209 m209 m

Laboratory Distribution Partners

70 70 70 70 70 70 70 90 90 90 90 100 100 100

Tests

105 k209 k318 k447 k121 k247.10 k377.50 k515.20 k164.36 k327.16 k494.33 k668.60 k200.19 k394.66 k
Show all operating metrics

Natera Revenue Breakdown

Embed Graph

Natera revenue breakdown by business segment: 6.7% from Licensing and Other and 93.3% from Genetic Tests

Natera revenue breakdown by geographic segment: 8.1% from Europe, Middle East, India, Africa, 87.7% from United States and 4.2% from Other

Natera Online and Social Media Presence

Embed Graph

Natera News and Updates

Natera Announces Third Quarter 2019 Earnings Conference Call

SAN CARLOS, Calif., Oct. 30, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2019, after the market close on November 6, 2019. Natera will host a conference...

Natera stock falls after hours on secondary-offering announcement

Natera Inc. shares fell in the extended session Tuesday after the DNA test company announced a secondary offering of its stock. Natera shares fell 6% after hours, following a 2.7% gain to close the regular session at $39.22. The company said it plans to offer $175 million in shares, with underwrite…

Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business

SAN CARLOS, Calif., Oct. 3, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will review recent progress in its oncology business, including the positive draft local coverage decision for Signatera™ in colorectal cancer and...

Natera Appoints Rowan Chapman to its Board of Directors

SAN CARLOS, Calif., Aug. 29, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has appointed Rowan Chapman, Ph.D., to its board of directors, effective August 15, 2019. "We are extremely pleased to welcome Dr. Rowan Chapman to our board and look...

Natera to Webcast Live Presentation at the Baird 2019 Global Healthcare Conference

SAN CARLOS, Calif., Aug. 28, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Baird 2019 Global Healthcare Conference at the InterContinental New York Barclay hotel in New York City on...

Natera Announces Second Quarter 2019 Earnings Conference Call

SAN CARLOS, Calif., July 31, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2019, after the market close on August 7, 2019. Natera will host a conference call...
Show more

Natera Blogs

Natera Reports Third Quarter 2019 Financial Results

SAN CARLOS, Calif., Nov. 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2019 and provided an update on recent business progress.…

October 15, 2019

October 15, 2019 Natera Launches Proposed Follow-On Offering CTA Links:  Read More Site source url:  https://www.natera.com/press-releases/natera-launches-proposed-follow-offering-1

September 24, 2019

September 24, 2019 Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring CTA Links:  https://www.natera.com/press-releases/foundation-medicine-and-natera-partner-adv... Site source url:  https://www.natera.com/press-releases/foundation-medicine-and-natera-partner-advance-personalized-cancer-monitoring…

Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

CAMBRIDGE, Mass. and SAN CARLOS, Calif., September 24, 2019 – Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA) today announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical customers who or…

CBR to Acquire Natera's Evercord™ Cord Blood Business

Sharpens Natera's Focus on Reproductive Health, Oncology and Organ Transplant SAN CARLOS, Calif., Sept. 13, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) and CBR (Cord Blood Registry) today announced the acquisition by CBR, a California Cryobank Life Sciences company, and the world's largest new…

Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

High positive predictive value shown for common chromosomal aneuploidies in all women, including women under 35 years of age SAN CARLOS, Calif., Sept. 9, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of the largest non-in…
Show more

Natera Frequently Asked Questions

  • When was Natera founded?

    Natera was founded in 2004.

  • Who are Natera key executives?

    Natera's key executives are Jonathan Sheena, Mike Brophy and Steven Chapman.

  • How many employees does Natera have?

    Natera has 975 employees.

  • What is Natera revenue?

    Latest Natera annual revenue is $257.7 m.

  • What is Natera revenue per employee?

    Latest Natera revenue per employee is $264.3 k.

  • Who are Natera competitors?

    Competitors of Natera include 23andMe, Ambry Genetics and Complete Genomics.

  • Where is Natera headquarters?

    Natera headquarters is located at 201 Industrial Rd suite 410, San Carlos.

  • Where are Natera offices?

    Natera has an office in San Carlos.

  • How many offices does Natera have?

    Natera has 1 office.